Hepatic haemangiomas are the most common primary liver tumours. This protocol addresses benign liver tumour management specifically in the setting of a confirmed hepatic haemangioma, with particular attention to complications including Kasabach-Merritt syndrome.
Management centres on referral to a benign liver tumour multidisciplinary team (MDT). Where Kasabach-Merritt syndrome is present, specific interventional and medical strategies are available; surgical considerations also apply in selected cases. The full protocol details the criteria and clinical decision points.
Hepatic haemangiomas are the most common primary liver tumours.
In the presence of Kasabach-Merrit syndrome, growing lesions or lesions symptomatic by compression — refer to benign liver tumour MDT (evidence level III, grade of recommendation 1).
Transcatheter hepatic embolization can be considered to manage the KMS, as can medical therapy with corticosteroids or vincristine.
Again, surgical resection is rarely indicated, except in the presence of KMS.
DOI: 10.1016/j.jhep.2016.04.001
View source ↗